newsfilter
← Latest News
Business Wire·

Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026

Presentations include investigational late-breaking KERENDIA® (finerenone) data in chronic kidney disease (CKD), including a pooled analysis from studies in patients with and without diabetes and a subanalysis in